APA (7th ed.) Citation

KW, L., DY, Z., HD, K., JW, K., BJ, K., YK, K., . . . HK, K. (2025). Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer. British journal of cancer, 133(2), 274. https://doi.org/10.1038/s41416-025-03092-4

Chicago Style (17th ed.) Citation

KW, Lee, Zang DY, Kim HD, Kim JW, Kim BJ, Kang YK, Ryu MH, and Kim HK. "Correction: Multicenter Phase Ib/II Study of Second-line Durvalumab and Tremelimumab in Combination with Paclitaxel in Patients with Biomarker-selected Metastatic Gastric Cancer." British Journal of Cancer 133, no. 2 (2025): 274. https://doi.org/10.1038/s41416-025-03092-4.

MLA (9th ed.) Citation

KW, Lee, et al. "Correction: Multicenter Phase Ib/II Study of Second-line Durvalumab and Tremelimumab in Combination with Paclitaxel in Patients with Biomarker-selected Metastatic Gastric Cancer." British Journal of Cancer, vol. 133, no. 2, 2025, p. 274, https://doi.org/10.1038/s41416-025-03092-4.